Artrya Limited · ASX:AYA
Artrya — Investor Presentation (September 2025)
12 slides from Artrya's investor presentation, Sep 1, 2025
Slide 1: Reshaping the Future of Heart Care
For personal use only (ASX: AYA) Presentation 01 September 2025 [ Reshaping the Future of [ Heart Care Not for Release to U.S. wire services or distribution in the United States
Slide 2: Important Notice
Important Notice IMPORTANT NOTICE AND DISCLAIMER The Presentation Materials contain summary information about the Company and its activities which is current as at the date of the Presentation Materials. The information in the Presentation Materials is of a general nature and does not purport These
Slide 3: Highlights
Highlights Salix® is a point-of-care solution that enhances clinician decision making and improves patient outcomes 1 Every 40 seconds in the US, someone suffers a heart attack1. More people die from heart disease than all cancers combined2. 2 For personal use only Artrya’s cloud-based, AI-driven Sa
Slide 4: Current methods for diagnosing coronary artery disease are outdated
Current methods for diagnosing coronary artery disease are outdated A point of care solution for rapidly diagnosing high risk plaque is a holy grail for clinicians For personal use only Ineffective Avoidable Old methods ineffective in detecting high- 55% of invasive procedures are risk plaque1 unnec
Slide 5: Salix is unique in providing real-time patient assessment
Salix® is unique in providing real-time patient assessment Clear clinical insights for coronary artery disease from a single solution Point of care enabling real-time – without humans For personal use only Plaque analysis from CCTA scans in under 10 mins without human intervention Detailed Plaque an
Slide 6: Seamlessly fits into workflow
Seamlessly fits into workflow Salix® is system agnostic and simple to deploy, use, and update Onsite Manual Assessment Current Separate solution for CCTA Read and Report Approach Review & Prepare Report For personal use only Manual assessment | No plaque assessment | Limited access to reimbursement
Slide 7: Coronary artery disease is a large and growing health challenge
Coronary artery disease is a large and growing health challenge Cardiovascular Disease Costs will Exceed $1 Trillion by 2035 - American Heart Association4 12.6 million For personal use only CCTA scans US$4.4 billion* (RoW)2 Serviceable Addressable Market (US) 6.2% YOY 4.4 Projected growth in Cardiac
Slide 8: Salix is a single platform solution built to scale
Salix® is a single platform solution built to scale Software modules target the complete analysis of CCTA scans for Coronary Artery Disease For personal use only Increasing clinical utility & Revenue opportunity • Final validation stage – anticipated submission to FDA in 4Q 2025 Salix® Coronary • Av
Slide 9: Salix platform successfully launched in the U.S.
Salix® platform successfully launched in the U.S. Tanner Health collaboration partnership to validate and integrate For personal use only Integrated and Live from July 2025 Next U.S. launch partners ► 5-year Commercial Agreement – US$0.6M ► Cone Health and Northeast Georgia Health System have been k
Slide 10: Flagship Novel Plaque Study – SAPPHIRE
Flagship Novel Plaque Study – SAPPHIRE Salix-based Analysis of Plaque to identify Patients at Higher Risk of Events The SAPPHIRE study will validate the novel Salix plaque analysis to identify patients at risk For personal use only of heart attack and improve treatment. Clinical and Commercial Benef
Slide 11: Key Takeaways
Key Takeaways Salix® is a point-of-care solution that enhances clinician decision making and improves patient outcomes 1 For personal use only Transitioned from development to commercialisation 2 Large growing market in the U.S. with established reimbursement codes 3 Salix® platform live in the U.S.
Slide 12: For personal use only
For personal use only www.artrya.com Corporate Enquiries Investor & Media Enquiries John Konstantopoulos David Allen or John Granger Co-Founder and Chief Executive Officer Hawkesbury Partners Tel: +61 8 6478 7816 Tel: +61 499 100 038 or +61 410 577 155 Email: contact@artrya.com Email: investors@artr